MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Sanofi

Gesloten

53.94 -1.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

53.77

Max

54.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.3B

499M

Verkoop

-6.5B

7.6B

K/W

Sectorgemiddelde

23.205

63.778

EPS

0.682

Dividendrendement

3.67

Winstmarge

6.539

Werknemers

82,878

EBITDA

-3.7B

563M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+19.16% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.67%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.5B

136B

Vorige openingsprijs

54.95

Vorige sluitingsprijs

53.94

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Sanofi Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mrt 2025, 06:43 UTC

Acquisities, Fusies, Overnames

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

3 feb 2025, 13:19 UTC

Acquisities, Fusies, Overnames

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

3 feb 2025, 09:31 UTC

Acquisities, Fusies, Overnames

Correction to L'Oreal article

3 feb 2025, 07:09 UTC

Acquisities, Fusies, Overnames

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

30 jan 2025, 11:09 UTC

Winsten

Correction to Sanofi Article

30 jan 2025, 06:47 UTC

Winsten

Sanofi Issues $5.2 Billion Share Buyback; Expects Sales, Core Earnings Growth

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

20 mrt 2025, 06:05 UTC

Acquisities, Fusies, Overnames

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mrt 2025, 06:05 UTC

Acquisities, Fusies, Overnames

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mrt 2025, 06:04 UTC

Acquisities, Fusies, Overnames

Sanofi to Pay $600M Upfront

20 mrt 2025, 06:02 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mrt 2025, 06:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

19 feb 2025, 06:35 UTC

Acquisities, Fusies, Overnames

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 feb 2025, 06:34 UTC

Acquisities, Fusies, Overnames

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 feb 2025, 06:34 UTC

Acquisities, Fusies, Overnames

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 feb 2025, 06:32 UTC

Acquisities, Fusies, Overnames

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 feb 2025, 06:31 UTC

Acquisities, Fusies, Overnames

Sanofi, CD&R Sign Opella Share Purchase Agreement

3 feb 2025, 06:37 UTC

Acquisities, Fusies, Overnames

Sanofi Says Transaction Is Part of Its Share Buyback Program

3 feb 2025, 06:35 UTC

Acquisities, Fusies, Overnames

L'Oreal: Sale Should Be Finalized in Coming Days

3 feb 2025, 06:35 UTC

Acquisities, Fusies, Overnames

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

3 feb 2025, 06:34 UTC

Acquisities, Fusies, Overnames

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

3 feb 2025, 06:33 UTC

Acquisities, Fusies, Overnames

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

3 feb 2025, 06:32 UTC

Acquisities, Fusies, Overnames

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

3 feb 2025, 06:31 UTC

Acquisities, Fusies, Overnames

L'Oreal to Sell Sanofi Stake for EUR3B

3 feb 2025, 06:31 UTC

Acquisities, Fusies, Overnames

L'Oreal to Sell Sanofi Stake Back to Sanofi

30 jan 2025, 10:47 UTC

Marktinformatie
Winsten

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

30 jan 2025, 10:31 UTC

Marktinformatie
Winsten

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

Peer Vergelijking

Prijswijziging

Sanofi Prognose

Koersdoel

By TipRanks

19.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 64.75 USD  19.16%

Hoogste 67 USD

Laagste 63 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

53.98 / 55.4Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.